What is the share price of Symbiotec Pharmalab Limited (SYMBIOTEC) today?
The share price of SYMBIOTEC as on 18th September 2026 is ₹1074.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Symbiotec Pharmalab Limited (SYMBIOTEC) share?
The past returns of Symbiotec Pharmalab Limited (SYMBIOTEC) share are- Past 1 week: -7.47%
- Past 1 month: 4.35%
- Past 3 months: N/A%
- Past 6 months: -4.80%
- Past 1 year: -4.80%
- Past 3 years: N/A%
- Past 5 years: -4.80%
What are the peers or stocks similar to Symbiotec Pharmalab Limited (SYMBIOTEC)?
The peers or stocks similar to Symbiotec Pharmalab Limited (SYMBIOTEC) include:What is the market cap of Symbiotec Pharmalab Limited (SYMBIOTEC) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Symbiotec Pharmalab Limited (SYMBIOTEC) is ₹6718.62 Cr as of 18th September 2026.What is the 52 week high and low of Symbiotec Pharmalab Limited (SYMBIOTEC) share?
The 52-week high of Symbiotec Pharmalab Limited (SYMBIOTEC) is ₹1193.70 and the 52-week low is ₹934.20.What is the PE and PB ratio of Symbiotec Pharmalab Limited (SYMBIOTEC) stock?
The P/E (price-to-earnings) ratio of Symbiotec Pharmalab Limited (SYMBIOTEC) is 61.15. The P/B (price-to-book) ratio is 5.84.Which sector does Symbiotec Pharmalab Limited (SYMBIOTEC) belong to?
Symbiotec Pharmalab Limited (SYMBIOTEC) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Symbiotec Pharmalab Limited (SYMBIOTEC) shares?
You can directly buy Symbiotec Pharmalab Limited (SYMBIOTEC) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Symbiotec Pharmalab Limited
SYMBIOTEC Share Price
NSE₹1,074.652.84% (+29.65)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SYMBIOTEC Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadInsufficient Data
Red flags
LowNo red flag found
How to use scorecard? Learn more
SYMBIOTEC Performance & Key Metrics
SYMBIOTEC Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 5.84 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.79 | 5.87 | 0.48% |
SYMBIOTEC Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SYMBIOTEC Company Profile
Symbiotec Pharmalab Limited is an Indian pharmaceutical and biotechnology company focused on R&D, manufacturing over 60 corticosteroid and steroidal-hormone APIs using fermentation and complex chemical synthesis at two industrial-scale API facilities in Rau, Mhow, Indore and Pithampur SEZ, Madhya Pradesh, supplying global markets.
BIOCON
PE Ratio
160.52
160.52
1Y Return
7.80%
7.80%
Buy Reco %
69.23
69.23
PE Ratio
88.26
88.26
1Y Return
7.46%
7.46%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
94.10
94.10
1Y Return
71.89%
71.89%
Buy Reco %
85.71
85.71
ACUTAAS
PE Ratio
76.18
76.18
1Y Return
125.13%
125.13%
Buy Reco %
88.89
88.89
ONESOURCE
PE Ratio
854.23
854.23
1Y Return
13.87%
13.87%
Buy Reco %
100.00
100.00
SYMBIOTEC Forecast
SYMBIOTEC Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SYMBIOTEC
SYMBIOTEC
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SYMBIOTEC Income Statement
SYMBIOTEC Income Statement
Quarterly Normal View
| Quarter | jun 2025 | |
|---|---|---|
| Total Revenue | 205.81 | |
Operating & Other expenses | 145.21 | |
EBITDA | 60.60 | |
| Depreciation/Amortization | 10.51 | |
| PBIT | 50.09 | |
| Interest & Other Items | 5.28 | |
| PBT | 44.81 | |
| Taxes & Other Items | 14.90 | |
| Net Income | 29.91 | |
| EPS | 5.47 |
SYMBIOTEC Company Updates
SYMBIOTEC Stock Peers
SYMBIOTEC Past Performance & Peer Comparison
SYMBIOTEC Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Symbiotec Pharmalab Limited | 61.15 | 5.84 | — |
| Biocon Limited | 160.52 | 1.69 | 0.13% |
| Anthem Biosciences Limited | 88.26 | 17.17 | 0.22% |
| Sai Life Sciences Limited | 94.10 | 13.22 | — |
SYMBIOTEC Stock Price Comparison
Compare SYMBIOTEC with any stock or ETFCompare SYMBIOTEC with any stock or ETF
SYMBIOTEC
SYMBIOTEC Holdings
SYMBIOTEC Shareholdings
SYMBIOTEC Promoter Holdings Trend
SYMBIOTEC Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SYMBIOTEC Institutional Holdings Trend
SYMBIOTEC Institutional Holdings Trend
No institutional holdings trend are available
SYMBIOTEC Shareholding Pattern
SYMBIOTEC Shareholding Pattern
SYMBIOTEC Shareholding History
SYMBIOTEC Shareholding History
Foreign Institutions
Mutual Funds Invested in SYMBIOTEC
Mutual Funds Invested in SYMBIOTEC
No mutual funds holding trends are available
Top 5 Mutual Funds holding Symbiotec Pharmalab Limited
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8930% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months 0.61% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 147/163 (+15) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6679% | Percentage of the fund’s portfolio invested in the stock 0.59% | Change in the portfolio weight of the stock over the last 3 months 0.59% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/70 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5954% | Percentage of the fund’s portfolio invested in the stock 1.21% | Change in the portfolio weight of the stock over the last 3 months 1.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/41 (+9) |
Compare 3-month MF holding change on Screener
smallcases containing SYMBIOTEC stock
smallcases containing SYMBIOTEC stock
Looks like this stock is not in any smallcase yet.
SYMBIOTEC Events
SYMBIOTEC Events
SYMBIOTEC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SYMBIOTEC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SYMBIOTEC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SYMBIOTEC has not given any dividends in last 5 years
SYMBIOTEC Dividends
SYMBIOTEC Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSYMBIOTEC Stock News & Opinions
SYMBIOTEC Stock News & Opinions
Articles & Videos
Corporate
Corporate
Symbiotec Pharmalab shares were re-pledged to Beacon Trusteeship Limited for a debentureSymbiotec Pharmalab Limited informed the BSE Limited and National Stock Exchange of India Limited on September 11, 2026, of re-created pledges of shares related to a debenture security agreement initially dated December 10, 2025. The pledges were made to Beacon Trusteeship Limited. Significant shareholdings were pledged by multiple entities, including Anil Satwani, Kashish Satwani, and various family trusts such as the Satwani Family Trust (Kashish and Anil Satwani Family Trust), the Arjun Anil Satwani Family Trust, and the Krishna Anil Satwani Family Trust. Anil Satwani and Kashish Satwani each pledged 21,99,104 shares, representing 3.42% of the total share capital, while the Satwani Family Trust (Anil Satwani) pledged 22,27,734 shares, constituting 3.47%. The re-creation of these pledges suggests a modification or replacement of a previous arrangement.
5 days agoCapital Market - Live
IPO
IPO
Symbiotec Pharmalab Ltd IPO subscribed 5.31 timesThe offer received bids for 6.97 crore units as against 1.31 crore units on offer. The initial public offer of Symbiotec Pharmalab Ltd IPO received bids for 6,96,65,865 units as against 1,31,24,929 units on offer, according to stock exchange data at 19:47 IST on Wednesday (26 August 2026). The issue was subscribed 5.31 times. The issue opened for bidding on Monday, 24 August 2026 and it will close on Thursday, 27 August 2026. The price band of the IPO is fixed at Rs 938 per share to 988 per share. An investor can bid for a minimum of 15 equity shares and in multiples thereof. The REIT IPO comprises a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore, aggregating to a total issue size of Rs 1,757 crore.
3 weeks agoCapital Market - Live
IPO
IPO
Symbiotec Pharmalab Ltd IPO subscribed 0.80 timesThe offer received bids for 1.05 crore units as against 1.31 crore units on offer. The initial public offer of Symbiotec Pharmalab Ltd IPO received bids for 1,05,37,575 units as against 1,31,24,929 units on offer, according to stock exchange data at 20:12 IST on Monday (24 August 2026). The issue was subscribed 0.80 times. The issue opened for bidding on Monday, 24 August 2026 and it will close on Thursday, 27 August 2026. The price band of the IPO is fixed at Rs 938 per share to 988 per share. An investor can bid for a minimum of 15 equity shares and in multiples thereof. The REIT IPO comprises a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore, aggregating to a total issue size of Rs 1,757 crore.
3 weeks agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.39%, vs industry avg of 18.09%
Over the last 5 years, market share decreased from 5.38% to 3.14%
Over the last 5 years, net income has grown at a yearly rate of -2.28%, vs industry avg of 11.18%